# Fostamatinib as a Single Agent or in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis With Severe Thrombocytopenia

Source: https://onco.cc/trials/nct04543279/  
OnCo record `nct04543279` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Fostamatinib and Ruxolitinib in Primary myelofibrosis, run by Washington University School of Medicine, recorded as terminated on the registry.

## Summary

Fostamatinib as a Single Agent or in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis With Severe Thrombocytopenia is a phase 2 interventional study registered as NCT04543279 by Washington University School of Medicine, with 3 participants recorded, started 2021-05-03 and due to reach its primary completion in 2022-07-01. Interventions recorded: Fostamatinib, Ruxolitinib. Conditions recorded: Myelofibrosis, Thrombocytopenia.

Linked to the drug Fostamatinib because the registry names it among its interventions and Primary myelofibrosis among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04543279
- Phase: 2
- Setting: Fostamatinib as a Single Agent or in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis With Severe Thrombocytopenia
- Sponsor: Washington University School of Medicine
- Enrolled: 3

## Sources

- ClinicalTrials.gov NCT04543279: https://clinicaltrials.gov/study/NCT04543279

## Connected records

- cancers: [Primary myelofibrosis](https://onco.cc/cancers/primary-myelofibrosis/)
- drugs: [Fostamatinib](https://onco.cc/drugs/fostamatinib/), [Ruxolitinib](https://onco.cc/drugs/ruxolitinib/)

---
JSON: https://onco.cc/api/v1/entities/nct04543279.json